<DOC>
	<DOCNO>NCT01858545</DOCNO>
	<brief_summary>The primary objective study ass effectiveness MatriStem device compare cellular dermal replacement tissue , treatment non-healing diabetic foot ulcer .</brief_summary>
	<brief_title>A Comparative Efficacy Study : Treatment Non-healing Diabetic Foot Ulcers</brief_title>
	<detailed_description>Due characteristically poor heal capacity , diabetic foot ulcer ( DFUs ) challenge clinician treat . This prospective , multi-center clinical study examine outcome follow treatment DFUs , one two FDA clear tissue-engineered device , MatriStemÂ® cellular dermal replacement tissue , DFUs demonstrate inadequate response initial standard care therapy . The incidence ulcer closure , rate wound closure , quality life evaluate eight week period .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Major Subject current diagnosis type I type II diabetes Subject 's ulcer forefoot heel Subject chronic ulcer present minimum 4 week Subject 's ulcer extend dermis subcutaneous tissue Subject 's HgbA1c &lt; 12 % Subject adequate circulation study foot evidence Doppler measure ABI great equal 0.7after 10 minute rest Major Subject know sensitivity bovine porcinederived product . Subject 's ulcer due nondiabetic etiology Subject 's ulcer Charcot deformity midfoot Subject 's random blood surgar reading &gt; 450 mg/dL Subject dialysis Subject nonstudy ulcer study limb locate within 7.0 cm study ulcer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>